The renal cell carcinoma market was valued at USD 5.00 Billion in 2025 and is expected to grow at a CAGR of 4.22%, reaching USD 7.56 Billion by 2035. The market growth is driven by rising cancer incidence and innovations in targeted therapies and immunotherapies.
Base Year
Historical Period
Forecast Period
Compound Annual Growth Rate
4.22%
Value in USD Billion
2026-2035
*this image is indicative*
Renal cell carcinoma (RCC) is the most frequent type of kidney cancer found in adults. RCC accounts for 80% to 85% of all primary renal tumors, and it typically affects men aged 50 to 70 years. With over 600,000 individuals affected by kidney cancer in the United States, the rising prevalence of the disease is expected to influence the renal cell carcinoma market growth significantly.
The surge in drug approvals by the health regulatory authorities is providing growth opportunities to the key players in the market. In September 2023 , the United States Food and Drug Administration (FDA) granted priority review designation to supplemental new drug application (sNDA) for belzutifan (Welireg) to treat advanced renal cell carcinoma. The clinical trial of the drug candidate demonstrated positive outcomes including reducing the risk of disease progression or death in metastatic RCC patients compared to another renal cell cancer drug Afinitor. The development of such drugs offering an alternative mechanism of action helps to cater to the unmet medical needs of the patients. Consequently, they are expected to drive the renal cell carcinoma market share in the forecast period.
The market is also driven by the rising healthcare expenditure and growing demand for personalized therapeutics. Moreover, the rising geriatric population with increased susceptibility to renal cell carcinoma will also help in the market growth.
"Renal Cell Carcinoma Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Indication Type
By indication type, the market includes chromophobe RCC, papillary RCC, clear cell RCC, and others. This market segment represents different subtypes of renal cell carcinoma, each with a distinct approach to diagnosis and treatment.
Market Breakup by Treatment Type
The treatment types for renal cell carcinoma include surgery, chemotherapy, targeted therapy, ablation, medication, and others. These approaches are used to manage, target at inhibiting tumor growth or alleviating symptoms.
Market Breakup by Diagnosis
The renal cell carcinoma market report includes segmentation based on diagnostics as well. Biopsy, ultrasound, blood tests, nephrectomy, CT scans, and urine tests, among others are common diagnostic methods. These tools help detect renal cell carcinoma and monitor disease progression.
Market Breakup by Dosage Form
By dosage form, the market is segmented into capsules, tablets, injections, and others. These dosage forms have different administration routes for delivering medications.
Market Breakup by Route of Administration
The renal cell carcinoma market is segmented by route of administration. It is divided into oral, parenteral, and other routes. This segment reflects how medications are delivered into the body for treating renal cell carcinoma.
Market Breakup by End User
End users of the market are hospitals, specialty clinics, homecare settings, and other healthcare facilities.
Market Breakup by Distribution Channel
The distribution channels of the market include hospital pharmacies, retail pharmacies, online pharmacies, and other channels. Serving as points of access for patients to obtain medications, these distribution channels contribute significantly to the renal cell carcinoma market demand.
Market Breakup by Region
The market report covers 8 major markets poised to witness significant growth in upcoming years. The region-based segmentation includes the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China. North America dominates the market share, which can be attributed to presence of a geriatric population base and the rising prevalence of renal cell carcinoma in the region. Moreover, the presence of key market leaders actively involved in research and development activities to commercialize effective therapeutics will also drive market growth in the coming years.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 4.22% during the forecast period of 2026-2035, driven by the rising prevalence of renal cell carcinoma across 8 major markets.
The market demand is driven by the advancement in targeted therapies and heightened patient awareness. Increasing investments to develop effective therapeutic alternatives is another factor driving market demand.
One of the significant market trends is the rise in fast-track designations and accelerated approvals from regulatory bodies. In September 2023, the United States FDA granted priority review designation to supplemental new drug application (sNDA) for belzutifan (Welireg) to treat advanced renal cell carcinoma.
Based on the indication type, the market is segmented into chromophobe RCC, papillary RCC, clear cell RCC, and others.
By dosage form, the market is segmented into capsules, tablets, injections, and others.
The route of administration includes oral, parenteral, and other routes.
The treatment types of the market are surgery, chemotherapy, targeted therapy, ablation, medication, and others.
Major end users of the market are hospitals, specialty clinics, homecare settings, and other healthcare facilities.
Distribution channels in the market include hospital pharmacies, retail pharmacies, online pharmacies, and other channels.
Diagnostic methods available in the market include biopsy, ultrasound, blood tests, nephrectomy, CT scans, urine tests, and others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and China.
Key players involved in the market are Bausch Health Companies Inc., LEO Pharma A/S, Merck KGaA, AbbVie Inc., Abbott, Cipla Inc., Johnson & Johnson Private Limited, AstraZeneca, Merck & Co., Inc., Mylan N.V., Eli Lilly and Company, Bayer AG, Novartis AG, GlaxoSmithKline plc, and Pfizer.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication Type |
|
| Breakup by Treatment Type |
|
| Breakup by Diagnosis |
|
| Breakup by Dosage Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share